We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amylin Eyes Bydureon Resubmission in Second Half of Year
Amylin Eyes Bydureon Resubmission in Second Half of Year
January 28, 2011
Amylin Pharmaceuticals says it plans to resubmit its NDA for its once-weekly diabetes drug, Bydureon, in the second half of this year.